Present Status and Future Perspectives of Heart Transplantation

Toyoda, Yoshiya; Guy, T. Sloane; Kashem, Abul

doi:10.1253/circj.cj-13-0296

Cited by 79 publications

(54 citation statements)

References 75 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…1) In heart transplantation, to clarify the mechanisms of CAV is crucial for developing effective diagnosis, prevention and therapeutic strategies.…”

Section: Discussionmentioning

confidence: 99%

“…1,4,17) The animal models of CAV were reported from rodents to large animals. The distinctive differences between rodents and swine are immune systems and cardiovascular systems.…”

Section: Discussionmentioning

confidence: 99%

“…6) The mechanisms of development of CAV and its prevention have been widely studied. [1][2][3][4][5][6][7] It is suggested that CAV development begins as a "response to injury," initial endothelial dysfunction followed by intimal hyperplasia as a result of vascular remodeling in response to initial reperfusion injury and repetitive immunological transplant-related endothelial injury. 2) These vascular remodeling and smooth muscle cell (SMC) proliferation are potentiated by inflammatory cytokines, growth factors, and chemotactic factors produced by activated endothelial cells and migrating cells, resulting in the activation of SMC and their migration from the media to the intima.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Characteristics of Cardiac Allograft Vasculopathy Induced by Immunomodulation in the Miniature Swine

Amano

Akashima

Terasaki

et al. 2015

ATCS

View full text Add to dashboard Cite

“…1) In heart transplantation, to clarify the mechanisms of CAV is crucial for developing effective diagnosis, prevention and therapeutic strategies.…”

Section: Discussionmentioning

confidence: 99%

“…1,4,17) The animal models of CAV were reported from rodents to large animals. The distinctive differences between rodents and swine are immune systems and cardiovascular systems.…”

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Characteristics of Cardiac Allograft Vasculopathy Induced by Immunomodulation in the Miniature Swine

Amano

Akashima

Terasaki

et al. 2015

ATCS

View full text Add to dashboard Cite

“…The more quickly the blood flow is restored, the better the outlook. Current therapies include surgical procedures such as coronary bypass, balloon angioplasty, stents and heart transplant as a last option [4]. Surgical interventions are generally combined/complemented with pharmacological treatments in order to improve patient outcomes [5].…”

Section: Myocardial Infarction and Current Treatmentsmentioning

confidence: 99%

“…In this study, Puramatrix TM , a commercial variant of RADA16 peptide, was used to create self-assembling hydrogel that underwent gelation in presence of salts from the body. Authors seeded 2x10 4 BMSC, SM, ADSC or CPC in such systems and injected them onto the infarcted area of a mouse MI model. 2 weeks after treatment CPC-hydrogel significantly attenuated infarct size expansion, improved echocardiography parameters and favored neoangiogenesis.…”

Section: Hydrogels In Cell-based Therapiesmentioning

confidence: 99%

Heart regeneration after myocardial infarction using synthetic biomaterials

Pascual-Gil

Garbayo

Díaz-Herráez

et al. 2015

Journal of Controlled Release

122

View full text Add to dashboard Cite

Abstract:Myocardial infarction causes almost 7.3 million deaths each year worldwide. However, current treatments are more palliative than curative. Presently, cell and protein therapies are considered the most promising alternative treatments. Clinical trials performed until now have demonstrated that these therapies are limited by protein short half-life and by low transplanted cell survival rate, prompting the development of novel cell and protein delivery systems able to overcome such limitations. In this review we discuss the advances made in the last 10 years in the emerging field of cardiac repair using biomaterial-based delivery systems with focus on the progress made on preclinical in vivo studies. Then, we focus in cardiac tissue engineering approaches, and how the incorporation of both cells and proteins together into biomaterials has opened new horizons in the myocardial infarction treatment. Finally, the ongoing challenges and the perspectives for future work in cardiac tissue engineering will also be discussed.

show abstract